- Home
- NVCR
NVCR
NovoCure Limited
as 05-08-2025 4:00pm EST
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 1.9B | IPO Year: | 2015 |
| Target Price: | $32.83 | AVG Volume (30 days): | 861.0K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.17 - $34.13 | Next Earning Date: | 04-24-2025 |
| Revenue: | $621,711,000 | Revenue Growth: | 18.27% |
| Revenue Growth (this year): | 2.9% | Revenue Growth (next year): | 10.47% |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paravasthu Mukund | NVCR | Chief Operating Officer | May 3 '25 | Sell | $17.91 | 592 | $10,604.20 | 83,556 | |
| Weinberg Uri | NVCR | Chief Innovation Officer | Mar 3 '25 | Sell | $18.67 | 4,905 | $92,020.26 | 166,243 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Mar 3 '25 | Sell | $18.54 | 2,527 | $46,841.23 | 143,673 | |
| Cordova Ashley | NVCR | Chief Executive Officer | Mar 3 '25 | Sell | $18.54 | 2,053 | $38,055.02 | 204,005 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | Mar 3 '25 | Sell | $18.54 | 250 | $4,634.08 | 83,556 | |
| Weinberg Uri | NVCR | Chief Innovation Officer | Feb 28 '25 | Sell | $18.55 | 4,637 | $86,949.24 | 166,243 | |
| Leonard Frank X | NVCR | EVP, Pres., Novocure Oncology | Feb 27 '25 | Sell | $19.59 | 30,072 | $592,513.68 | 143,673 | |
| Puri Michal Nath | NVCR | Chief Human Resources Officer | Feb 27 '25 | Sell | $20.24 | 2,774 | $55,545.55 | 108,706 | |
| Cordova Ashley | NVCR | Chief Executive Officer | Feb 27 '25 | Sell | $19.59 | 26,988 | $532,252.59 | 204,005 | |
| Leupin Nicolas | NVCR | Chief Medical Officer | Feb 27 '25 | Sell | $20.24 | 1,982 | $39,687.13 | 50,133 |
Latest NovoCure Limited News
NVCR Breaking Stock News: Dive into NVCR Ticker-Specific Updates for Smart Investing
Zacks
10 days ago
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Motley Fool
14 days ago
Why NovoCure Stock Skyrocketed This Week
Motley Fool
14 days ago
Why NovoCure Stock Leaped 4% Higher Today
Zacks
15 days ago
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
MT Newswires
15 days ago
NovoCure's Q1 Loss Narrows, Revenue Rises
Zacks
15 days ago
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
15 days ago
NovoCure: Q1 Earnings Snapshot
Business Wire
15 days ago
Novocure Reports First Quarter 2025 Financial Results
Compare NVCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.